Nasdaq
Every company in the roster listed on Nasdaq.
Every company in the roster listed on Nasdaq.
292 of 292 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Savara Inc.SVRA · Nasdaq | 1 asset: 1 Ph 3 | molgramostimPhase 3 · Autoimmune Pulmonary Alveolar ProteinosisReliable signal | Jun 2027molgramostim · Phase 3 | $1.2B | $130MSep 2026 | ~4.0 qtrs | $91M |
Nektar TherapeuticsNKTR · Nasdaq | 2 assets: 1 Ph 3, 1 other | rezpegaldesleukinPhase 3 · Atopic DermatitisPartial signal | May 2028rezpegaldesleukin · Phase 3 | $1.2B | $614MSep 2026 | ~9.6 qtrs | $149M |
KardiganKARD · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | DanicamtivPhase 3 · Heart FailureWeak signal | Dec 2026Tonlamarsen · Phase 2 | $1.2B | $472MSep 2026 | ~8.9 qtrs | $189M |
LB PharmaceuticalsLBRX · Nasdaq | 1 asset: 1 Ph 3 | LB-102 (methylated amisulpride)Phase 3 · SchizophreniaReliable signal | None on record | $1.1B | $404MSep 2026 | ~11.3 qtrs | $119M |
Mineralys TherapeuticsMLYS · Nasdaq | 1 asset: 1 Ph 3 | LorundrostatPhase 3 · HypertensionReliable signal | None on record | $1.1B | $625MSep 2026 | ~16.3 qtrs | $293M |
GH ResearchGHRS · Nasdaq | 1 asset: 1 Ph 2 | Mebufotenin (5-MeO-DMT)Phase 2 · Major Depressive DisorderPartial signal | None on record | $1.1B | $246MDec 2025 | ~22.6 qtrs | $39M |
COMPASS PathwaysCMPS · Nasdaq | 1 asset: 1 Ph 3 | Psilocybin (COMP360)Phase 3 · Major Depressive DisorderReliable signal | Nov 2028Psilocybin (COMP360) · Phase 2/3 | $1.1B | $444MSep 2026 | ~10.1 qtrs | $109M |
Jade Biosciences, Inc.JBIO · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | JADE101Phase 3 · IgA Nephropathy | May 2027JADE101 · Phase 1 | $1.1B | $476MSep 2026 | ~14.6 qtrs | $145M |
Vor BioVOR · Nasdaq | 1 asset: 1 Ph 3 | TelitaciceptPhase 3 · Rheumatoid ArthritisReliable signal | 31 Dec 2026Telitacicept · Phase 3 | $1.1B | $482MSep 2026 | ~16.2 qtrs | $97M |
Omeros CorporationOMER · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $1.1B | $132MJun 2026 | ~7.7 qtrs | $63M |
Seaport TherapeuticsSPTX · Nasdaq | 1 asset: 1 Ph 2 | GlyphAllo (allopregnanolone prodrug)Phase 2 · Major Depressive Disorder | Mar 2027GlyphAllo (allopregnanolone prodrug) · Phase 2 | $980M | $290MSep 2026 | ~13.7 qtrs | ~$90M |
MoonLake ImmunotherapeuticsMLTX · Nasdaq | 1 asset: 1 Ph 3 | sonelokimabPhase 3 · Psoriatic ArthritisReliable signal | 4 Jan 2027sonelokimab · Phase 3 | $875M | $501MSep 2026 | ~8.2 qtrs | $230M |
Verastem, Inc.VSTM · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | GFH375Phase 3 · Non-Small Cell Lung Cancer | 30 Apr 2027GFH375 · Phase 2 | $866M | $173MSep 2026 | ~12.3 qtrswith a later raise | $180M |
Corvus PharmaceuticalsCRVS · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | soquelitinibPhase 3 · Peripheral T-Cell LymphomaWeak signal | 30 Dec 2026soquelitinib · Phase 1 | $860M | $203MSep 2026 | ~18.0 qtrs | $55M |
| 3 assets: 3 approved | Approved assets only | None on record | $806M | $166MSep 2026 | Cash-flow positive | $7.0M | |
ORIC PharmaceuticalsORIC · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | RinzimetostatPhase 3 · Prostate Cancer | Dec 2026Enozertinib · Phase 1 | $793M | $265MJun 2026 | ~9.5 qtrs | $122M |
Ironwood PharmaceuticalsIRWD · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | apraglutidePhase 3 · Short Bowel Syndrome | None on record | $791M | $86MSep 2026 | Cash-flow positive | $95M |
ArdelyxARDX · Nasdaq | 2 assets: 2 approved | Approved assets only | 26 Feb 2027Tenapanor (Ibsrela) · Phase 3 | $784M | $285MSep 2026 | 10+ years | $94M |
Lexicon PharmaceuticalsLXRX · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | PilavapadinPhase 2 · Diabetic Peripheral Neuropathic PainPartial signal | Jan 2027Sotagliflozin (Inpefa) · Phase 3 | $766M | $183MSep 2026 | ~14.9 qtrs | $58M |
Climb Bio, Inc.CLYM · Nasdaq | 1 asset: 1 Ph 2 | budoprutugPhase 2 · Primary Membranous Nephropathy | Apr 2027budoprutug · Phase 1 | $756M | $206MSep 2026 | ~15.6 qtrs | $44M |
Attovia TherapeuticsATTO · Nasdaq | 1 asset: 1 Ph 1 | ATTO-1310Phase 1 · Atopic Dermatitis | 30 Aug 2028ATTO-1310 · Phase 2 | $709M | $396MSep 2026 | ~19.4 qtrs | ~$65M |
Nuvectis PharmaNVCT · Nasdaq | 1 asset: 1 Ph 1 | NXP900Phase 1 · Non-Small Cell Lung Cancer | Dec 2026NXP900 · Phase 1 | $698M | $141MSep 2026 | ~36.0 qtrs | $41M |
Kura Oncology, Inc.KURA · Nasdaq | 2 assets: 1 approved, 1 Ph 1 | DarlifarnibPhase 1 · Non-Small Cell Lung Cancer | Dec 2026Ziftomenib · Phase 1 | $674M | $492MSep 2026 | ~11.6 qtrs | $258M |
Annexon, Inc.ANNX · Nasdaq | 3 assets: 2 Ph 3, 1 Ph 1 | VonaprumentPhase 3 · Age-Related Macular DegenerationPartial signal | 31 May 2027tanruprubart · Phase 3 | $667M | $214MSep 2026 | ~4.5 qtrs | $166M |
InventivaIVA · Nasdaq | 1 asset: 1 Ph 3 | LanifibranorPhase 3 · MASH / NASHPartial signal | None on record | $655M | $100MDec 2024 | ~9.1 qtrswith a later raise | $98M |
Geron CorporationGERN · Nasdaq | 1 asset: 1 approved | Approved assets only | Feb 2027Imetelstat · Phase 1 | $638M | $286MSep 2026 | ~12.7 qtrs | $63M |
Janux TherapeuticsJANX · Nasdaq | 1 asset: 1 Ph 1 | JANX007Phase 1 · Prostate Cancer | Jul 2027JANX007 · Phase 1 | $631M | $946MSep 2026 | 10+ years | $120M |
AlumisALMS · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | EnvudeucitinibPhase 3 · PsoriasisReliable signal | 1 Dec 2027Envudeucitinib · Phase 2 | $560M | $433MSep 2026 | ~5.4 qtrs | $330M |
Aclaris TherapeuticsACRS · Nasdaq | 4 assets: 3 Ph 2, 1 other | BosakitugPhase 2 · Atopic DermatitisWeak signal | Mar 2029Modzatinib · Phase 2 | $555M | $114MSep 2026 | ~6.5 qtrs | $66M |
Wave Life SciencesWVE · Nasdaq | 4 assets: 4 Ph 2 | WVE-003Phase 1/2 · Huntington's DiseaseWeak signal | Sep 2027WVE-006 · Phase 1/2 | $546M | $431MSep 2026 | ~8.3 qtrs | $205M |
ArriVent BioPharmaAVBP · Nasdaq | 1 asset: 1 Ph 3 | FurmonertinibPhase 3 · Non-Small Cell Lung Cancer | Dec 2026Furmonertinib · Phase 3 | $537M | $393MSep 2026 | ~10.3 qtrs | $151M |
Gyre TherapeuticsGYRE · Nasdaq | 1 asset: 1 other | F230Pulmonary Arterial Hypertension | None on record | $500M | $57MSep 2026 | ~9.9 qtrs | $17M |
Aquestive Therapeutics, Inc.AQST · Nasdaq | 3 assets: 1 approved, 1 Ph 3, 1 other | Diazepam (Libervant)Phase 3 · EpilepsyWeak signal | None on record | $475M | $90MSep 2026 | ~9.1 qtrs | $16M |
Capricor TherapeuticsCAPR · Nasdaq | 1 asset: 1 Ph 3 | deramiocelPhase 3 · Duchenne Muscular Dystrophy | None on record | $467M | $199MSep 2026 | ~6.6 qtrs | $109M |
DiaMedica TherapeuticsDMAC · Nasdaq | 1 asset: 1 Ph 3 | Rinvecalinase alfaPhase 2/3 · Acute Ischemic Stroke | Dec 2026Rinvecalinase alfa · Phase 2/3 | $463M | $35MSep 2026 | ~4.1 qtrs | $32M |
Assembly BiosciencesASMB · Nasdaq | 1 asset: 1 Ph 1 | ABI-5366Phase 1 · Genital Herpes | None on record | $458M | $314MSep 2026 | ~31.0 qtrs | $67M |
Cypherpunk Technologies Inc.CYPH · Nasdaq | 1 asset: 1 Ph 2 | SirexatamabPhase 2 · Colorectal Cancer | None on record | $440M | $7.6MJun 2026 | Ended Nov 2026 | $2.6M |
Helus PharmaHELP · Nasdaq | 1 asset: 1 Ph 3 | DeupsilocinPhase 3 · Major Depressive DisorderPartial signal | None on record | $427M | — | — | $39M |
Tectonic TherapeuticTECX · Nasdaq | 1 asset: 1 Ph 2 | Fc-relaxin fusion protein (TX45)Phase 2 · Pulmonary Hypertension Associated with Interstitial Lung Disease | 24 Nov 2026Fc-relaxin fusion protein (TX45) · Phase 2 | $420M | $235MSep 2026 | ~13.6 qtrs | $73M |
Candel Therapeutics, Inc.CADL · Nasdaq | 1 asset: 1 Ph 3 | Aglatimagene BesadenovecPhase 3 · Non-Small Cell Lung Cancer | Feb 2027Aglatimagene Besadenovec · Phase 2 | $417M | $204MSep 2026 | ~11.8 qtrs | $56M |
Avalo Therapeutics, Inc.AVTX · Nasdaq | 2 assets: 2 Ph 2 | QuisovalimabPhase 2 · AsthmaPartial signal | None on record | $387M | $393MSep 2026 | ~24.8 qtrs | $66M |
Jasper Therapeutics, Inc.JSPR · Nasdaq | 1 asset: 1 Ph 2 | BriquilimabPhase 1/2 · Chronic Spontaneous UrticariaPartial signal | None on record | $383M | $7.7MJun 2026 | Ended Aug 2026 | $37M |
Opus Genetics, Inc.IRD · Nasdaq | 1 asset: 1 Ph 3 | OPGx-LCA5Phase 3 · Leber Congenital Amaurosis | 15 Jun 2028OPGx-LCA5 · Phase 1/2 | $379M | $89MSep 2026 | ~7.3 qtrs | $47M |
Puma BiotechnologyPBYI · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | AlisertibPhase 2 · Small Cell Lung Cancer | 30 Oct 2027Alisertib · Phase 2 | $373M | $109MSep 2026 | Cash-flow positive | $74M |
ARS Pharmaceuticals, Inc.SPRY · Nasdaq | 1 asset: 1 approved | Approved assets only | Apr 2027Epinephrine · Approved | $367M | $138MSep 2026 | ~3.0 qtrs | $31M |
CorMedixCRMD · Nasdaq | 1 asset: 1 approved | Approved assets only | Jan 2028Taurolidine/heparin · Phase 3 | $351M | $356MSep 2026 | Cash-flow positive | $30M |
Adlai Nortye Biopharma Co., Ltd.ANL · Nasdaq | 1 asset: 1 Ph 2 | PalupiprantPhase 2 · Non-Small Cell Lung CancerWeak signal | None on record | $350M | $61MDec 2024 | Ended Mar 2026 | $45M |
Lyell Immunopharma, Inc.LYEL · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | Rondecabtagene autoleucelPhase 3 · Large B-Cell Lymphoma | Jun 2028LYL273 · Phase 1/2 | $341M | $179MSep 2026 | ~5.1 qtrs | $170M |
Prelude TherapeuticsPRLD · Nasdaq | 1 asset: 1 Ph 2 | PRT3789Phase 2 · Non-Small Cell Lung CancerWeak signal | None on record | $340M | $152MJun 2026 | ~6.1 qtrs | $108M |
Immunic, Inc.IMUX · Nasdaq | 2 assets: 1 Ph 3, 1 other | vidofludimus calciumPhase 3 · Multiple Sclerosis | Nov 2026vidofludimus calcium · Phase 3 | $328M | $132MSep 2026 | ~5.5 qtrs | $95M |
ProKidneyPROK · Nasdaq | 1 asset: 1 Ph 3 | RilparencelPhase 3 · Chronic Kidney DiseaseWeak signal | Dec 2029Rilparencel · Phase 3 | $314M | $81MSep 2026 | ~2.1 qtrs | $145M |
MapLight TherapeuticsMPLT · Nasdaq | 1 asset: 1 Ph 2 | Betovumeline/fesoterodine (ML-007C-MA)Phase 2 · Alzheimer's DiseasePartial signal | Dec 2027Betovumeline/fesoterodine (ML-007C-MA) · Phase 2 | $309M | $305MJun 2026 | ~7.0 qtrs | $199M |
Galectin Therapeutics Inc.GALT · Nasdaq | 1 asset: 1 Ph 3 | belapectinPhase 2/3 · MASH / NASHPartial signal | None on record | $301M | $13MJun 2026 | ~2.7 qtrs | $8.9M |
Autolus Therapeutics plcAUTL · Nasdaq | 1 asset: 1 approved | Approved assets only | Sep 2027obecabtagene autoleucel · Phase 1 | $282M | $250MSep 2026 | ~5.7 qtrs | $116M |
Eikon TherapeuticsEIKN · Nasdaq | 1 asset: 1 Ph 3 | ResiquimodPhase 2/3 · Non-Small Cell Lung Cancer | Dec 2026Resiquimod · Phase 2 | $280M | $462MSep 2026 | ~8.2 qtrs | $269M |
Inhibikase TherapeuticsIKT · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | Imatinib mesylate prodrug (IkT-001Pro)Phase 3 · Pulmonary Arterial Hypertension | Jun 2029Imatinib mesylate prodrug (IkT-001Pro) · Phase 3 | $277M | $193MSep 2026 | ~15.7 qtrs | $46M |
C4 Therapeutics, Inc.CCCC · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | CemsidomidePhase 2 · Multiple Myeloma | Jun 2027CFT8919 · Phase 1 | $274M | $209MSep 2026 | ~10.5 qtrs | $99M |
AltimmuneALT · Nasdaq | 1 asset: 1 Ph 3 | pemvidutidePhase 3 · MASH / NASHReliable signal | 30 Sep 2027pemvidutide · Phase 2 | $270M | $265MSep 2026 | ~10.4 qtrs | $80M |
Q32 BioQTTB · Nasdaq | 1 asset: 1 Ph 2 | BempikibartPhase 2 · Atopic DermatitisPartial signal | None on record | $255M | $290MSep 2026 | 10+ years | $16M |
Allogene Therapeutics, Inc.ALLO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | cemacabtagene ansegedleucelPhase 2 · Large B-Cell Lymphoma | Dec 2027cemacabtagene ansegedleucel · Phase 2 | $240M | $303MSep 2026 | ~11.2 qtrs | $133M |
Amarin CorporationAMRN · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $236M | $323MSep 2026 | Cash-flow positive | $19M |
Lexeo TherapeuticsLXEO · Nasdaq | 1 asset: 1 Ph 2 | LX1001Phase 1/2 · Alzheimer's DiseaseWeak signal | Nov 2028LX1001 · Phase 1 | $232M | $215MJun 2026 | ~9.7 qtrs | $67M |
Vanda PharmaceuticalsVNDA · Nasdaq | 6 assets: 4 approved, 2 Ph 3 | ImsidolimabPhase 3 · PsoriasisPartial signal | 1 Dec 2026tradipitant · Phase 3 | $227M | $141MSep 2026 | ~4.6 qtrs | $122M |
Faeth Therapeutics, Inc.FTH · Nasdaq | 4 assets: 3 Ph 2, 1 other | SerabelisibPhase 2 · Endometrial CancerWeak signal | Sep 2028Serabelisib · Phase 2 | $225M | $175MSep 2026 | ~16.2 qtrs | — |
AC ImmuneACIU · Nasdaq | 3 assets: 3 Ph 2 | ACI-35.030Phase 2 · Alzheimer's DiseasePartial signal | 22 Dec 2026ACI-35.030 · Phase 2 | $214M | $115MDec 2025 | ~5.5 qtrs | $68M |
Palisade BioPALI · Nasdaq | 1 asset: 1 Ph 2 | PALI-2108Phase 2 · Ulcerative ColitisWeak signal | Oct 2027PALI-2108 · Phase 2 | $205M | $114MSep 2026 | ~18.3 qtrs | $31M |
PRECISION BIOSCIENCES INCDTIL · Nasdaq | 1 asset: 1 Ph 1 | Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis | 1 Dec 2026Azercabtagene zapreleucel · Phase 1 | $198M | $108MSep 2026 | ~8.4 qtrs | $53M |
Cartesian Therapeutics, Inc.RNAC · Nasdaq | 1 asset: 1 Ph 3 | Descartes-08Phase 3 · Myasthenia Gravis | 1 Dec 2026Descartes-08 · Phase 2 | $192M | $125MSep 2026 | ~5.6 qtrs | $70M |
Alpha Cognition Inc.ACOG · Nasdaq | 1 asset: 1 approved | Approved assets only | Apr 2027Benzgalantamine · Approved | $187M | $38MSep 2026 | ~5.0 qtrs | $5.0M |
COMPUGEN LTDCGEN · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | RilvegostomigPhase 3 · Non-Small Cell Lung Cancer | Mar 2027COM701 · Phase 1/2 | $185M | $100MDec 2025 | Cash-flow positive | $23M |
Inovio Pharmaceuticals, Inc.INO · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $175M | $48MSep 2026 | ~2.6 qtrs | $46M |
Pyxis OncologyPYXS · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | MW02Phase 2/3 · Age-Related Macular DegenerationPartial signal | 25 Apr 2027Micvotabart pelidotin · Phase 1 | $168M | $56MSep 2026 | ~8.9 qtrswith a later raise | $74M |
Xilio TherapeuticsXLO · Nasdaq | 1 asset: 1 Ph 2 | XTX501Phase 1/2 · Non-Small Cell Lung Cancer | Nov 2029XTX501 · Phase 1/2 | $154M | $124MSep 2026 | ~8.7 qtrs | $67M |
| 3 assets: 3 Ph 1 | BBO-10203Phase 1 · Non-Small Cell Lung Cancer | Aug 2027BBO-10203 · Phase 1 | $145M | $194MSep 2026 | ~5.1 qtrs | $157M | |
Sutro Biopharma, Inc.STRO · Nasdaq | 1 asset: 1 Ph 1 | STRO-004Phase 1 · Non-Small Cell Lung Cancer | Dec 2027STRO-004 · Phase 1 | $141M | $142MSep 2026 | ~4.4 qtrs | $128M |
HumacyteHUMA · Nasdaq | 1 asset: 1 approved | Approved assets only | Jun 2027Human Acellular Vessel (Humacyte) · Phase 3 | $139M | $65MSep 2026 | ~2.9 qtrs | $66M |
ALX Oncology Inc.ALXO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | EvorpaceptPhase 2 · HER2-Positive Breast Cancer | Jun 2027ALX2004 · Phase 1 | $134M | $138MJun 2026 | ~7.8 qtrs | $62M |
Protara TherapeuticsTARA · Nasdaq | 1 asset: 1 Ph 3 | TARA-002Phase 3 · Non-Muscle Invasive Bladder Cancer | Dec 2026TARA-002 · Phase 2 | $132M | $128MSep 2026 | ~7.1 qtrs | $60M |
MacroGenicsMGNX · Nasdaq | 5 assets: 1 Ph 2, 4 Ph 1 | LorigerlimabPhase 2 | Nov 2026MGD024 · Phase 1 | $125M | $49MSep 2026 | ~4.9 qtrs | $138M |
Fate TherapeuticsFATE · Nasdaq | 4 assets: 1 Ph 2, 2 Ph 1, 1 other | FT819Phase 2 · Systemic Lupus Erythematosus | 30 Sep 2027FT819 · Phase 1 | $122M | $139MSep 2026 | ~5.3 qtrs | $99M |
NRx PharmaceuticalsNRXP · Nasdaq | 1 asset: 1 Ph 3 | D-cycloserine/lurasidone (NRX-101)Phase 3 · Bipolar Depression | None on record | $121M | $27MJun 2026 | ~5.4 qtrs | $5.4M |
Upstream BioUPB · Nasdaq | 1 asset: 1 Ph 2 | verekitugPhase 2 · Chronic Obstructive Pulmonary DiseaseReliable signal | Sep 2027verekitug · Phase 2 | $114M | $207MSep 2026 | ~4.9 qtrs | $149M |
Akebia TherapeuticsAKBA · Nasdaq | 3 assets: 1 approved, 2 Ph 2 | Ebribafusp alfaPhase 2 · IgA Nephropathy | Jun 2027Praliciguat · Phase 2 | $114M | $160MSep 2026 | Cash-flow positive | $72M |
Compass TherapeuticsCMPX · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | tovecimigPhase 2/3 · Biliary Tract Cancer | Dec 2026CTX-8371 · Phase 1 | $110M | $163MSep 2026 | ~10.6 qtrs | $69M |
Minerva NeurosciencesNERV · Nasdaq | 1 asset: 1 Ph 3 | RoluperidonePhase 3 · SchizophreniaPartial signal | Dec 2027Roluperidone · Phase 3 | $109M | $77MSep 2026 | ~9.8 qtrs | $20M |
Neonc Technologies, Inc.NTHI · Nasdaq | 2 assets: 1 Ph 2, 1 other | NEO212Phase 1/2 · Non-Small Cell Lung Cancer | 30 Dec 2026NEO100 · Phase 2 | $108M | $6.2MSep 2026 | ~1.2 qtrs | $6.5M |
Lexaria BioscienceLEXX · Nasdaq | 2 assets: 1 Ph 1, 1 other | DehydraTECH-CBD/semaglutidePhase 1 · ObesityWeak signal | None on record | $106M | $3.6MMay 2026 | Ended Oct 2026 | $5.3M |
NovaBridge BiosciencesNBP · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | UliledlimabPhase 2/3 · Non-Small Cell Lung Cancer | Dec 2026givastomig · Phase 1 | $104M | $211MDec 2025 | ~38.3 qtrs | $63M |
Voyager TherapeuticsVYGR · Nasdaq | 1 asset: 1 Ph 2 | VY7523Phase 1/2 · Alzheimer's Disease | None on record | $104M | $110MSep 2026 | ~4.0 qtrs | $107M |
Genelux CorporationGNLX · Nasdaq | 1 asset: 1 Ph 3 | Olvimulogene nanivacirepvecPhase 3 · Ovarian Cancer | Dec 2026Olvimulogene nanivacirepvec · Phase 3 | $101M | $19MJun 2026 | ~3.0 qtrs | $23M |
Unicycive TherapeuticsUNCY · Nasdaq | 1 asset: 1 Ph 2 | Oxylanthanum carbonatePhase 2 · Chronic Kidney DiseaseWeak signal | None on record | $99M | $61MJun 2026 | ~8.8 qtrs | $9.6M |
Cumberland Pharmaceuticals Inc.CPIX · Nasdaq | 1 asset: 1 Ph 2 | IfetrobanPhase 2 · Systemic SclerosisPartial signal | Jan 2028Ifetroban · Phase 2 | $99M | $81MSep 2026 | 10+ years | $4.6M |
TuHURA BiosciencesHURA · Nasdaq | 1 asset: 1 Ph 3 | IFx-2.0Phase 2/3 · Merkel Cell Carcinoma | 31 Mar 2027IFx-2.0 · Phase 2/3 | $87M | $1.9MSep 2026 | Ended Oct 2026 | $22M |
RANI TherapeuticsRANI · Nasdaq | 1 asset: 1 Ph 1 | RT-114Phase 1 | 1 Dec 2026RT-114 · Phase 1 | $80M | $3.8MSep 2026 | ~0.7 qtrs | $21M |
Tenax TherapeuticsTENX · Nasdaq | 1 asset: 1 Ph 3 | LevosimendanPhase 3 · Heart FailurePartial signal | 30 Jun 2028Levosimendan · Phase 3 | $77M | $114MSep 2026 | ~9.2 qtrs | $47M |
Neumora Therapeutics, Inc.NMRA · Nasdaq | 1 asset: 1 Ph 1 | NMRA-323511Phase 1 · Alzheimer's DiseasePartial signal | None on record | $69M | $117MJun 2026 | ~2.6 qtrs | $153M |
Anavex Life SciencesAVXL · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | BlarcamesinePhase 2/3 · Alzheimer's DiseasePartial signal | None on record | $67M | $118MJun 2026 | ~13.8 qtrs | $32M |
MediciNova, Inc.MNOV · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | IbudilastPhase 2/3 · Amyotrophic Lateral Sclerosis | 31 Dec 2026Tipelukast · Phase 2 | $65M | $29MSep 2026 | ~11.9 qtrs | $4.7M |
vTv TherapeuticsVTVT · Nasdaq | 3 assets: 2 Ph 3, 1 Ph 2 | Prifemilast (HPP737)Phase 3 · PsoriasisPartial signal | Apr 2027cadisegliatin · Phase 3 | $64M | $77MSep 2026 | ~14.2 qtrs | $29M |
Coherus BioSciences, Inc.CHRS · Nasdaq | 1 asset: 1 approved | Approved assets only | 15 Dec 2026Toripalimab · Phase 1 | $63M | $84MSep 2026 | ~1.9 qtrs | $97M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.